Fanatics Collectibles to Open Its First-Ever Global Flagship Store in the Spring of 2025, to Be Located on Iconic Regent Street in London
The Much-Anticipated Interactive Store Will Focus on Sports and Entertainment Trading Cards, Offer Exclusive Product and Host Events, Athletes and ClubsIncluded in Its Unique Footprint: An In-Store Breaking Area, a State-of-the-Art Trading-Card Singles Experience, Card Opening and Trading Areas and Customer Education Touchpoints
Today Fanatics Collectibles announced its first-ever flagship store, to open in the spring of 2025 on iconic Regent Street in London. The focus: sports and entertainment trading cards and trading-card games, featuring Fanatics Collectibles’ brands, including Topps, Merlin, Match Attax and Bowman. Last year Topps secured the exclusive trading-card rights to the Premier League, with product launching in time for the 2025/2026 season. Topps also currently has the exclusive rights for UEFA national team competitions and club competitions and will begin making licensed NBA product later this year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250122281845/en/
(Photo: Fanatics Collectibles)
The much-anticipated store will span 803 square meters (8,647 square feet), and give collectors a one-of-a-kind experience seven days a week. The stunning visual centerpiece: a central display of the rarest and most-desirable cards, all with a giant suspended circular screen above. The flagship will offer exclusive product and have thousands of unique items, inclusive of single cards, retail boxes and high-end hobby releases. It will also see highly trafficked community-building events from monthly trade nights, kids rip events, athlete signings and appearances, partner activations and grading drop-off. Along with retail space, the store will feature a state-of-the-art breaking studio (live and taped opening of card packs), interactive customer education touchpoints – and a personal card creation suite.
“We are incredibly excited to cut the ribbon on this amazing community-building retail space, one that we hope will delight collectors and be a true home for the hobby in Europe,” said Topps President of Trading Cards, David Leiner. “It’ll be a destination for millions of fans as well as our own internal partners – and team and club partners, the latter using our dedicated space to launch and showcase new products in a way that has never been done before.” Speaking to internal partners, the new store will serve as a drop-off point for users of Fanatics Collect, a dynamic marketplace that connects buyers and sellers of trading cards. To the flagship being a home for fans and collectors, currently there are less than five Topps-partner hobby shops in the UK, and less than 30 in all of Europe. The annual footfall of south Regent Street is more than 70 million people.
While the store will focus primarily on trading cards, other items will be sold, including apparel (both Topps-branded and Fanatics-owned Mitchell & Ness) and memorabilia (signed kits, jerseys, balls and other equipment) and trading-card supplies. Types of trading-card products in the store: sports (soccer, football, baseball, F1, basketball, UFC, WWE), sports gaming cards (Match Attax) and entertainment (Disney, Marvel, Star Wars, Pixar, Garbage Pail Kids, Stranger Things).
About Fanatics Collectibles
Fanatics Collectibles is a new model and vision for the hobby fundamentally changing the experience for current and future collectors, leagues, and players across many professional and college sports. The organization secured long-term, exclusive rights to design, manufacture and distribute trading cards for several sports and entertainment properties, including MLB, MLBPA, the Premier League, MLS, UFC, Formula 1 as well as Disney, Marvel, Pixar and Star Wars, among others. In January 2022, Fanatics Collectibles announced the acquisition of Topps, establishing the preeminent licensed trading card brand as the cornerstone of Fanatics’ trading cards and collectibles business and jumpstarted its MLB and MLBPA rights to design, manufacture and distribute trading cards.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250122281845/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom